TEL AVIV, Israel– Radiaction Medical, LTD (“Radiaction”), a medical device company whose mission is to provide radiation protection to the entire medical staff during interventional procedures, today announced that it has appointed industry veteran Christopher Barys to serve as its US President and Chief Commercial Officer. Barys will lead commercialization efforts and operations in the US.
“In the midst of a rapidly changing healthcare environment, protection for interventional staff has remained stagnant, to the detriment of those healthcare workers who are in the direct line of harm from scatter radiation,” Barys said. “Innovative, clinically supported solutions are needed now more than ever, and Radiaction is answering the call. I am proud to play a key role in its mission to bring forth a new model of advanced radiation protection to the healthcare providers that need it most.”
Barys joined Radiaction’s Board of Directors in 2023 and will remain on the board as he steps into his new role. Earlier this year, the company raised $12.6 million in Series C2 funding led by U.S. private equity fund InnovaHealth Partners with participation from additional co-investors. The company is currently focused on expanding its footprint in the United States, adding new sites to its user base, and growing its clinical publication pipeline to support the technology’s performance with clinical data.
Jonathan Yifat, Radiaction CEO, said, “When we met Chris, I knew he had the right experience and vision to steer Radiaction through our next stage of growth. With his extensive track record of market development within the interventional space, Chris is a tremendous asset to the strategic composition of our leadership team. I am excited to work alongside him in bringing our radiation protection solution to interventional teams across the country.”
